ロード中...
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high‐...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5055166/ https://ncbi.nlm.nih.gov/pubmed/27457217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.827 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|